Implications of the hybrid epithelial/mesenchymal phenotype in metastasis

Understanding cell-fate decisions during tumorigenesis and metastasis is a major challenge in modern cancer biology. One canonical cell-fate decision that cancer cells undergo is Epithelial-to-Mesenchymal Transition (EMT) and its reverse Mesenchymal-to-Epithelial Transition (MET). While transitioning between these two phenotypes - epithelial and mesenchymal - cells can also attain a hybrid epithelial/mesenchymal (i.e. partial or intermediate EMT) phenotype. Cells in this phenotype have mixed epithelial (e.g. adhesion) and mesenchymal (e.g. migration) properties, thereby allowing them to move collectively as clusters of Circulating Tumor Cells (CTCs). If these clusters enter the circulation, they can be more apoptosis-resistant and more capable of initiating metastatic lesions than cancer cells moving individually with wholly mesenchymal phenotypes, having undergo a complete EMT. Here, we review the operating principles of the core regulatory network for EMT/MET that acts as a three-way switch giving rise to three distinct phenotypes - epithelial, mesenchymal and hybrid epithelial/mesenchymal. We further characterize this hybrid E/M phenotype in terms of its capabilities in terms of collective cell migration, tumor-initiation, cell-cell communication, and drug resistance. We elucidate how the highly interconnected coupling between these modules coordinates cell-fate decisions among a population of cancer cells in the dynamic tumor, hence facilitating tumor-stoma interactions, formation of CTC clusters, and consequently cancer metastasis. Finally, we discuss the multiple advantages that the hybrid epithelial/mesenchymal phenotype have as compared to a complete EMT phenotype and argue that these collectively migrating cells are the primary ‘bad actors’ of metastasis.

💡 Research Summary

The review tackles a paradigm shift in our understanding of cancer metastasis by focusing on the hybrid epithelial/mesenchymal (E/M) phenotype rather than the classical binary view of epithelial‑to‑mesenchymal transition (EMT) followed by a complete mesenchymal state. The authors first describe the core regulatory circuitry that governs EMT/MET, emphasizing mutually inhibitory feedback loops such as miR‑200/ZEB, SNAIL/SLUG versus OVOL, and the integration of extrinsic cues (TGF‑β, Wnt, Notch). Mathematical and experimental evidence supports the notion that this circuitry functions as a three‑way switch, yielding three stable attractors: a purely epithelial state, a purely mesenchymal state, and a hybrid E/M state where both epithelial adhesion molecules (E‑cadherin, claudins) and mesenchymal motility factors (N‑cadherin, vimentin) are co‑expressed at intermediate levels.

The hybrid state endows cancer cells with unique functional capabilities. Because partial epithelial traits are retained, cells can remain adherent to one another, enabling collective migration as clusters of circulating tumor cells (CTCs). These clusters are markedly more resistant to shear stress, anoikis, and immune surveillance (especially NK‑cell mediated killing) than single mesenchymal cells. The review highlights the role of Notch‑Jagged lateral induction in synchronizing the hybrid phenotype across cluster members, thereby stabilizing the collective behavior.

Beyond migration, hybrid E/M cells exhibit heightened tumor‑initiating potential. They frequently co‑express stem‑cell markers such as CD44⁺/CD24⁻ and ALDH, and they secrete cytokines (IL‑6, IL‑8) and growth factors (EGF, HGF) that remodel the tumor microenvironment, promote angiogenesis, and facilitate niche formation at distant sites. Consequently, hybrid clusters act as “seeds” that can efficiently colonize secondary organs after extravasation.

Drug resistance is another hallmark of the hybrid phenotype. The simultaneous activation of EMT‑associated transcription factors (SNAIL, TWIST) and antioxidant pathways (NRF2, glutathione metabolism) confers cross‑resistance to conventional chemotherapies (e.g., paclitaxel, doxorubicin) and targeted agents (EGFR inhibitors). Moreover, the physical architecture of CTC clusters limits drug penetration, while intercellular signaling within the cluster amplifies survival pathways, creating a robust protective niche.

Therapeutically, the authors argue that targeting the hybrid state requires a multi‑pronged approach. Strategies may include restoring miR‑200 levels, inhibiting Notch‑Jagged signaling, disrupting cluster integrity (e.g., anti‑platelet agents or agents that block cell‑cell adhesion), and combining these with conventional therapies to overcome resistance. Clinically, detection of hybrid CTC clusters in blood using combined epithelial and mesenchymal markers could serve as a powerful prognostic tool and guide personalized treatment decisions.

In conclusion, the hybrid epithelial/mesenchymal phenotype is not a transient intermediate but a stable, plastic state that maximizes metastatic fitness. It integrates collective migration, stemness, immune evasion, and drug resistance into a single cellular program, making hybrid clusters the primary “bad actors” of metastasis. Understanding and disrupting this program is therefore essential for the next generation of anti‑metastatic therapies.